Results 1 to 10 of about 35,302 (150)

Long‐Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Rhythm control with class 1C antiarrhythmic drugs (AADs) is a widely used treatment among patients with atrial fibrillation (AF), but cardiovascular benefits of class 1C pharmacotherapy over rate control strategy are still unclear.
Aditya Bhonsale, Yisi Wang, Floyd Thoma, Krishna Kancharla, Andrew Voigt, Alaa Shalaby, Aditi Naniwadekar, Virginia Singla, N. A. Estes, Samir Saba, Suresh Mulukutla, Sandeep Jain   +11 more
doaj   +2 more sources

Investigation of 1,4-Substituted 1,2,3-Triazole Derivatives as Antiarrhythmics: Synthesis, Structure, and Properties

Pharmaceuticals, 2022
Here, we investigated the reaction of 1,3-dipolar cycloaddition of 1,3-diazido-2-nitro-2- azapropane (DANP) to propargyl alcohol over a copper-based catalyst and identified the optimum reaction conditions that enable the synthesis of 2-nitro-1,3-bis(4,4′-
Elena O. Shestakova, Sergey G. Il’yasov, Irina A. Shchurova, Vera S. Glukhacheva, Dmitri S. Il’yasov, Egor E. Zhukov, Arkady O. Bryzgalov, Tatiana G. Tolstikova, Yuri V. Gatilov   +8 more
doaj   +1 more source

Antiarrhythmic Drug Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy

Biomedicines, 2023
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable progressive myocardial disorder that predisposes patients to ventricular arrhythmias and sudden cardiac death.
Sean P. Gaine, Hugh Calkins
doaj   +1 more source

Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner

Frontiers in Pharmacology, 2021
Atomoxetine, a neuroactive drug, is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). It is primarily known as a high affinity blocker of the noradrenaline transporter, whereby its application leads to an increased level of ...
Karl Josef Föhr, Ariadni Nastos, Michael Fauler, Thomas Zimmer, Bettina Jungwirth, David Alexander Christian Messerer   +5 more
doaj   +1 more source

Synthesis and In Vivo Antiarrhythmic Activity Evaluation of Novel Scutellarein Analogues as Voltage-Gated Nav1.5 and Cav1.2 Channels Blockers

Molecules, 2023
Malignant cardiac arrhythmias with high morbidity and mortality have posed a significant threat to our human health. Scutellarein, a metabolite of Scutellarin which is isolated from Scutellaria altissima L., presents excellent therapeutic effects on ...
Wei Yang, Wenping Wang, Song Cai, Peng Li, Die Zhang, Jinhua Ning, Jin Ke, Anguo Hou, Linyun Chen, Yunshu Ma, Wenbin Jin   +10 more
doaj   +1 more source

Physicochemical stability of 20 mg/mL amiodarone hydrochloride oral suspension in SyrSpend® SF PH4 (liquid)

Pharmaceutical Technology in Hospital Pharmacy, 2022
Amiodarone hydrochloride is a class III antiarrhythmic drug indicated for the treatment of ventricular and supraventricular tachycardias. Oral amiodarone is only available in a tablet dosage form, which is not suitable for pediatric use. The stability of
Adoum Anissa, Le Pho Viet Anh Diane, Faisant Sophie, Legendre Pauline, Lester Marie-Antoinette, Boivin Pierre-Nicolas   +5 more
doaj   +1 more source

Attenuation and Structural Transformation of Crassicauline A During Sand Frying Process and Antiarrhythmic Effects of its Transformed Products

Frontiers in Pharmacology, 2021
To ensure safety and efficacy, most Aconitum herbs should be processed before clinical application. The processing methods include boiling, steaming, and sand frying.
Pei Tao, Yan Wang, Yujie Wang
doaj   +1 more source

Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines

Frontiers in Pharmacology, 2022
Introduction: In human pharmacology, there are two important scientific branches: clinical pharmacology and pharmacoepidemiology. Pharmacokinetic/pharmacodynamic (PK/PD) modeling is important in preclinical studies and randomized control trials. However,
Soroush Mohammadi Jouabadi, Soroush Mohammadi Jouabadi, Mitra Nekouei Shahraki, Payam Peymani, Bruno H. Stricker, Fariba Ahmadizar, Fariba Ahmadizar   +6 more
doaj   +1 more source

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

Frontiers in Pharmacology, 2020
Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management.
Meng Geng, Andrew Lin, Thao P. Nguyen
doaj   +1 more source

Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Chronic kidney disease (CKD) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control.
Jeffrey B. Washam, DaJuanicia N. Holmes, Laine E. Thomas, Sean D. Pokorney, Elaine M. Hylek, Gregg C. Fonarow, Kenneth W. Mahaffey, Bernard J. Gersh, Peter R. Kowey, Jack E. Ansell, Alan S. Go, James A. Reiffel, James V. Freeman, Daniel E. Singer, Gerald Naccarelli, Rosalia Blanco, Eric D. Peterson, Jonathan P. Piccini   +17 more
doaj   +1 more source